The drug binding site of human alpha1-acid glycoprotein: insight from induced circular dichroism and electronic absorption spectra.
暂无分享,去创建一个
[1] Narasimha Sreerama,et al. Computation and Analysis of Protein Circular Dichroism Spectra , 2004, Numerical Computer Methods, Part D.
[2] Sato,et al. Characterization of the Chromophore Orientation of Rhodamine B Amphiphiles in Langmuir-Blodgett Monolayers. , 2001, Journal of colloid and interface science.
[3] Y. Saito,et al. Calorimetry studies of chlorpromazine hydrochloride in solution , 2000 .
[4] M. Tabak,et al. SYNTHESIS, CHARACTERIZATION AND INTERACTION WITH IONIC MICELLES OF TETRAACETYLATED DIPYRIDAMOLE , 1995 .
[5] P. McNamara,et al. Autacoid binding to serum proteins. Interaction of platelet activating factor (PAF) with human serum alpha-1-acid glycoprotein (AAG). , 1986, Biochemical pharmacology.
[6] K. Nakanishi,et al. Quantitative definition of exciton chirality and the distant effect in the exciton chirality method , 1975 .
[7] B Testa,et al. Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. , 1998, Molecular pharmacology.
[8] R. Sonders. Pharmacokinetics of terazosin. , 1986, The American journal of medicine.
[9] W. Schaper. Dipyridamole, an Underestimated Vascular Protective Drug , 2005, Cardiovascular drugs and therapy.
[10] M. Otagiri,et al. Characterization of Drug Binding Sites on α1-Acid Glycoprotein , 1990 .
[11] L. Cubeddu,et al. Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. , 1986, Journal of pharmaceutical sciences.
[12] Yoshihisa Inoue,et al. The pH dependence of the anisotropy factors of essential amino acids , 2002 .
[13] U. Westphal,et al. Steroid-protein interactions. XXXIV. Chemical modification of alpha1-acid glycoprotein for characterization of the progesterone binding site. , 1976, Biochimica et biophysica acta.
[14] Z. Bikádi,et al. Induced chirality upon crocetin binding to human serum albumin: origin and nature , 2001 .
[15] I. Polyakova,et al. Crystal structure of the 1:2.5 molecular complex of the internal salt of [6-(diethylamino)-9-[2-(fluorosulfonyl)-4-sulfophenyl]-3h-xanthen-3-ylidene]diethylammonium hydroxide with ethanol , 1985 .
[16] K. Hanada,et al. Enantioselective Binding of Propranolol, Disopyramide, and Verapamil to Human α1‐Acid Glycoprotein , 2000 .
[17] W. Müller,et al. Characterization of a common binding site for basic drugs on human α2-acid glycoprotein (orosomucoid) , 1983, Naunyn-Schmiedeberg's Archives of Pharmacology.
[18] J. Barré,et al. Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycop , 1996, Pharmacogenetics.
[19] T. Maruyama,et al. Further characterization of reversal of signs of induced cotton effects of dicumarol derivatives-alpha 1-acid glycoprotein systems by protriptyline. , 1992, Biochemical pharmacology.
[20] F. Zsila,et al. Circular dichroism and absorption spectroscopic data reveal binding of the natural cis-carotenoid bixin to human α1-acid glycoprotein , 2005 .
[21] H. Matsunaga,et al. Multiple ligand-binding properties of the lipocalin member chicken alpha1-acid glycoprotein studied by circular dichroism and electronic absorption spectroscopy: the essential role of the conserved tryptophan residue. , 2006, Biochimica et biophysica acta.
[22] Z H Israili,et al. HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS†,‡ , 2001, Drug metabolism reviews.
[23] R. Farinotti,et al. Enantioselective chromatography of the antimalarial agents chloroquine, mefloquine, and enpiroline on a α1-acid glycoprotein chiral stationary phase : evidence for a multiple-site chiral recognition mechanism , 1992 .
[24] J. Albani. Tertiary structure of human alpha1-acid glycoprotein (orosomucoid). Straightforward fluorescence experiments revealing the presence of a binding pocket. , 2004, Carbohydrate research.
[25] T. Imai,et al. A comparative study of the interaction of warfarin with human α1‐acid glycoprotein and human albumin , 1987, The Journal of pharmacy and pharmacology.
[26] A. Skerra,et al. Comparative ligand-binding analysis of ten human lipocalins. , 2006, Biochimica et biophysica acta.
[27] H. Halsall,et al. Fluorescence quenching of human orosomucoid. Accessibility to drugs and small quenching agents. , 1985, The Biochemical journal.
[28] M. Sugawara,et al. Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. , 2003, British journal of clinical pharmacology.
[29] M. Otagiri,et al. A molecular functional study on the interactions of drugs with plasma proteins. , 2005, Drug metabolism and pharmacokinetics.
[30] L. H. Chen,et al. Topography of human plasma alpha1-acid glycoprotein. , 1976, Biochemistry.
[31] F. Brunner,et al. Prazosin binding to human α1‐acid glycoprotein (orosomucoid), human serum albumin, and human serum. Further characterization of the 'single drug binding site' of orosomucoid , 1985, The Journal of pharmacy and pharmacology.
[32] K. Schmid. Preparation and Properties of Serum and Plasma Proteins. XXIX. Separation from Human Plasma of Polysaccharides, Peptides and Proteins of Low Molecular Weight. Crystallization of an Acid Glycoprotein1a,b,c , 1953 .
[33] H. Halsall,et al. The lipocalin model for human orosomucoid: Support from the chromatography of orosomucoid-monoclonal antibody complexes , 1994 .
[34] D. Raines,et al. Development of a novel probe for measuring drug binding to the F1*S variant of human alpha 1-acid glycoprotein. , 2001, Journal of pharmaceutical sciences.
[35] G. Bandoli,et al. X-ray crystallographic characterization of 10,11-dihydro-5H-dibenz[b, f ]azepine-5-carboxamide , 1992 .
[36] Rüdiger Ettrich,et al. Structure of human α1-acid glycoprotein and its high-affinity binding site , 2003 .
[37] T. Burghardt,et al. Conformation of xanthene dyes in the sulfhydryl 1 binding site of myosin. 2. , 1995, Biochemistry.
[38] Ulrich Westphal,et al. Steroid-Protein Interactions , 1971, Monographs on Endocrinology.
[39] Z. Bikádi,et al. Induced circular dichroism spectra reveal binding of the antiinflammatory curcumin to human alpha1-acid glycoprotein. , 2004, Bioorganic & medicinal chemistry.
[40] S. Mason,et al. Linear and circular dichroism studies of DNA-monoaminoacridine complexes , 1971 .
[41] M. Tabak,et al. Electronic absorption and fluorescence spectroscopic studies of dipyridamole: Effects of solution composition , 1992 .
[42] T. Hazlett,et al. Optical spectroscopy in studies of antibody-hapten interactions. , 2000, Methods.
[43] E. Zola,et al. Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin and alpha 1-acid glycoprotein. , 1984, British journal of clinical pharmacology.
[44] T. Imai,et al. Drug Binding to α1-Acid Glycoprotein Studied by Circular Dichroism , 2004, Pharmaceutical Research.
[45] M. Otagiri,et al. Investigation of the Interaction Mode of Phenothiazine Neuroleptics with α1‐Acid Glycoprotein , 1992 .
[46] E. Nanba,et al. Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S , 1997, Human Genetics.
[47] J. Albani. Progesterone binding to the tryptophan residues of human α1-acid glycoprotein , 2006 .
[48] H. Frischer,et al. Distribution of primaquine in human blood: drug-binding to alpha 1-glycoprotein. , 1990, The Journal of laboratory and clinical medicine.
[49] G. Brett,et al. Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands. , 2000, Pharmacological reviews.
[50] J. D. Bell,et al. The crystal structure of phenothiazine , 1968 .
[51] N. Yamaotsu,et al. Use of Photoaffinity Labeling and Site-directed Mutagenesis for Identification of the Key Residue Responsible for Extraordinarily High Affinity Binding of UCN-01 in Human α1-Acid Glycoprotein* , 2005, Journal of Biological Chemistry.
[52] J. Kremer,et al. Drug binding to human alpha-1-acid glycoprotein in health and disease. , 1988, Pharmacological reviews.
[53] F. Zsila,et al. Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein. , 2006, Biochimica et biophysica acta.
[54] U. Wollert,et al. Binding of several phenothiazine neuroleptics to a common binding site of alpha 1-acid glycoprotein, orosomucoid. , 1983, Journal of pharmaceutical sciences.
[55] J. Schley. Inhibitory effect of phenothiazines on the binding of [3H]perazine to α1‐acid glycoprotein , 1987 .
[56] Z. Bikádi,et al. Specific ligand binding on genetic variants of human alpha1-acid glycoprotein studied by circular dichroism spectroscopy. , 2004, Biochemical pharmacology.